chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Discharge Provider: MD Primary Care Provider at Discharge: DO Admission Date: 6/22/2022 Discharge Date: 06/25/2022  Chief Complaint Patient presents with ? COUGH     Positive COVID via home test today. Family concerned because they stated he had a reading of 78% O's on room air. EMS stated he was 98 for them, without intervention or s/s of distress.    Patient is an 85-year-old man with a past medical history of atrial fibrillation on anticoagulation, multiple cardiac elements, type 2 diabetes mellitus, and vascular dementia who was admitted to Hospital on June 22, 2022 for weakness associated with COVID-19 infection.  Upon his arrival patient had stable vital signs.  He was physically deconditioned and work with physical therapy and occupational therapy.  Upon the recommendation the patient will be receiving home health care services including physical therapy and occupational therapy.   The patient did test positive for COVID-19.  It is unclear the duration of his symptoms and his vaccination status.  He is not a candidate for Decadron or remdesivir as he was never hypoxic.  He received supportive care with Tylenol and cough suppressant.   During patient's hospitalization he did have 1 episode of atrial fibrillation with rapid ventricular rates.  He did receive IV Lopressor with good response.  The patient's home medications including digoxin and metoprolol were resumed and his rates have remained controlled for greater than 24 hours.  He will be discharged home with continuation of his home medications in stable condition.
Myalgia throughout my muscles and joints. Severe myalgia and stiffness at injection site. Chills and fever. Lethargy.
Pt vaccinated with MMR/HIB developed acute cerebella ataxia, maculopapular rash, fever of 102.
PATIENT GOT VACCINE SAT. MORNING, SAYS BY EVENING HAD MUCLE ACH AND INSOMNIA. NEXT MORNING FELT HOT AND WAS SWEATING ALONG WITH NAUSEA. AFTER PT TRIED TO USE RESTROOM FAINTED. PT SAYS WAS NOT OUT FOR LONG BUT POSSIBLE HIT HEAD. SAYS DOING BETTER BY TODAY
Painful ulcerations in R tongue, hard & soft palate & eustachian tube opening. Resultant pain w/swallowing.
Cold; Cough; Fever; Tiredness; This is a spontaneous report from a contactable adult female consumer reported for her Husband.   A 32-year-old male patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Batch/Lot number was not reported), via an unspecified route of administration, administered in left arm on 25Mar2021 at 08:30 AM (at the age of 32-years-old) at dose 1, single for COVID-19 immunisation. Medical history included asthma (asthma did not continue and did not experience at the time of report, but he had experienced it earlier). Concomitant medications were none. On 25Mar2021, same day of vaccination, in the evening, the patient experienced cold, cough, fever and tiredness. It was reported that after the patient got vaccine in the day, from night onwards he got fever and tiredness (exact time was not known but in the evening). The fever stayed for 3 continuous days and he was fine a bit after that, and the fever stayed for till like Saturday, and Sunday he was fine and Monday also he was fine a bit. But today he is (incomplete sentence). Side effects like fever and cough, a bit of cold were still present at the time of report. The patient underwent lab tests and procedures which included SARS-CoV-2 test: Negative on an unspecified date in 2021. The patient did not receive treatment for the events. The outcome of events cold, cough and fever was not recovered, and unknown for tiredness.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Patient was admitted for a scheduled vitrectomy surgery. Per the EUA, hospitalizations are to be reported irrespective of attribution to vaccine.
Rash developed on mouth on 6/7/19; Spread to chest, back, and lower legs. Had 12m vaccines on 5/28/2019
This spontaneous report received from a medical assistant referred to a 51 year old patient of unknown gender. The patient's medical history and concurrent conditions were not reported. The patient was administered RECOMBIVAX HB (dose, lot and expiry date not reported) on 23-MAY-2011, 28-JUN-2011 and 26-SEP-2011 (inappropriate schedule of drug administration). A titre was perfomed on an unspecified date and the results were negative for hepatitis B (Hepatitis B antibody negative). Concomitant medication included VAQTA taken on 29-JUN-2017. Outcome of Hepatitis B antibody negative was unknown. Causality assessment was not reported. Additional information is not expected as consent to contact is not provided.
This case was reported by a consumer via call center representative and described the occurrence of injection site pain in a 82-year-old female patient who received SHINGRIX for prophylaxis. On 5th November 2018, the patient received SHINGRIX. On 5th November 2018, several days after receiving SHINGRIX, the patient experienced injection site pain, injection site swelling and injection site warmth. On an unknown date, the outcome of the injection site pain, injection site swelling and injection site warmth were recovering/resolving. It was unknown if the reporter considered the injection site pain, injection site swelling and injection site warmth to be related to SHINGRIX. Additional details were reported as follows: The patient received the injection a day prior to the reporting date, at mid morning in the left arm and experienced pain, swelling and warm to touch at the injection site that evening. The patient said it was painful to lie in the arm. The patient did not give consent to be followed up.
Starting 06/03/2022, I had a sore throat. I took an at-home COVID-19 test and it was positive. I went to Urgent Care and they advised me to treat with over the counter medications for symptoms, rest and isolate myself. I did have a fever of no more than 100 during the breakthrough case. The day after testing positive, I did start feeling worse. Then, with each consecutive day starting 06/05/2022, I started to feel better. It took some time for me to return to normal energy levels. Sometime in the 2nd week of June I tested myself again and was still positive.
Client presented for second dose of Moderna vaccination, client was inadvertently given Pfizer for a second dose. The nurse administering the vaccination, acknowledged this error, and informed the client and his father. Both the client and his father were upset but voiced  understanding. Spoke with Bureau of Immunizations, and a spokesperson from there stated that this is still considered an appropriate vaccination dose and the client will not need to restart the series . Client and father aware.
Pt. received first dose of rabies vaccine (pre-exposure) on 8/5/08. 3 days after administration, she developed rash on arms, hand and back of legs. Pt stated that she had similar rash in past and felt it was unrelated to vaccine. 2nd dose of rabies vaccine given 8/12/08. 4 days after administration she developed a red itchy rash all over her body, but most on arms and legs. Also had swelling of upper lip and eyelid. Symptoms resolved with ZYRTEC & BENADRYL.
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 55-year-old male patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), as dose 3 (booster), single (Batch/Lot number: unknown), in right arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown) and as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "Treatment of COVID-19". Therapeutic measures were taken as a result of drug ineffective, covid-19.  The information on the batch/lot number for BNT162b2, BNT162b2 omi ba.4-5 has been requested and will be submitted if and when received.
Significant pain at injection site; bruise and warm area approx three inches around injection site; muscular pain in upper arm. Note no pain whatsoever at time of injection.
With no history of migraines in the past, there has been whole head pressure and daily migraines since the day after the first shot of the moderna vaccine. I am now going on day 32 of migraines daily, a mild ear ache, and constant head pressure. Advil helps somewhat but then the pain returns once the Advil wears off.
High fever 106.3, crying, vomiting, pain, fast heart beats, breathing fast, poor appetite.
patient received second dose 20 days after first dose; This spontaneous case was reported by a pharmacist and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (patient received second dose 20 days after first dose) in a 53-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 024C21A and 016C21A) for COVID-19 vaccination.     No Medical History information was reported.   On 28-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 18-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 18-May-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (patient received second dose 20 days after first dose). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (patient received second dose 20 days after first dose) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Action taken with mRNA-1273 in response to the events was not Applicable. Concomitant and treatment information not provided
No adverse effect reported; On 17-JUL-2019, the patient was administered properly stored PROQUAD instead of M-M-R II; On 17-JUL-2019, the patient was administered properly stored PROQUAD instead of M-M-R II; This spontaneous report was received from a medical assistant referring to a 55 year old-female patient. No information regarding patient's concurrent conditions, medical history, drug allergies or reactions were provided.       On 17-JUL-2019 , the patient was erroneously vaccinated  with  properly stored measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) lot # R020814, expiration date 16-JAN-2020 for prophylaxis (strength, dose, frequency, and route of administration were not provided) (product administered to patient of inappropriate age) instead of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) (wrong product administered ).  Properly stored sterile diluent used, and  no adverse effects were reported.     ,
Today, they both tested positive for COVID-19.; needing a nap; snotty nose; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team and product quality group. The reporter is the patient.  A 63-year-old female patient received bnt162b2 omi xbb.1.5 (COMIRNATY (2023-2024 FORMULA)), on 08Nov2023 as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: COVID-19 (non-serious) with onset 09Nov2023, outcome "unknown", described as "Today, they both tested positive for COVID-19."; SOMNOLENCE (non-serious) with onset Nov2023, outcome "unknown", described as "needing a nap"; RHINORRHOEA (non-serious) with onset Nov2023, outcome "unknown", described as "snotty nose". Relevant laboratory tests and procedures are available in the appropriate section. The information on the batch/lot number for bnt162b2 omi xbb.1.5 has been requested and will be submitted if and when received.  Additional information: seriousness was reported as no. she travelled during the weekend and got the Pfizer COVID-19 vaccine last evening. The caller wants to know if what the positive COVID-19 test is due to the vaccine.
Symptoms of Cough, runny nose, Headache, fatigue, muscle aches, fever, sore throat - diagnosed as COVID.  Symptom onset 5/17/2021.
SYMPTOMS OF SMALL BROWN BRUISE UNTIL 4 DAYS LATER OF THE 2ND SHOT. PROGRESSED TOWARDS BODY AND STARTED TO ITCH.
2/28/2021 patient noted bleeding while brushing teeth.   Over next week patient developed petechiae and bruises.    Required treatment with glucocorticoids and intravenous immunoglobulin.    Potential triggers include nifedipime (started 12/20) and COVID vaccine (1/21).
stated they started getting atopic dermatitus after vaccine; Drug Start date: May2021/ Date of start of drug: Aug2021; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP).  A 25-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), in Aug2021 as dose 2, single (Batch/Lot number: unknown) at the age of 24 years for covid-19 immunisation. The patient's relevant medical history included: "anxiety" (unspecified if ongoing), notes: anxiety and other. The patient took concomitant medications. Vaccination history included: Covid-19 vaccine (Dose Number: 1, Batch/Lot No: Unknown. Manufacturer unknown), administration date: May2021, when the patient was 24 years old, for COVID-19 immunization. The following information was reported: INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (non-serious) with onset Aug2021, outcome "unknown", described as "Drug Start date: May2021/ Date of start of drug: Aug2021"; DERMATITIS ATOPIC (non-serious) with onset Sep2021, outcome "recovered with sequelae", described as "stated they started getting atopic dermatitus after vaccine". The event "stated they started getting atopic dermatitus after vaccine" required physician office visit. Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were taken as a result of dermatitis atopic.  Additional information: Patient did not received any other vaccines within 4 weeks prior to the COVID vaccine. Patient received other medication within 2 weeks of vaccination. Adverse event result in multiple visits to dermatologist, biopsy and patient was on dupixent treatment. Patient was not diagnosed with COVID-19 prior to vaccination. Patient was not tested for COVID-19 since vaccination.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
There was no adverse event.  Patient was given a second dose of Fluzone HD.  This would have been her second immunization. She received one on  8/19/2020.  Patient showed no signs or symptoms of adverse event.
Swelling, moderate to severe pain in left arm, redness and weakness in left arm; nausea and diarrhea X 3 days post injection.
Vaccine administered after more than 1 temperature excursion; Vaccine administered after more than 1 temperature excursion; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccine administered after more than 1 temperature excursion) and POOR QUALITY PRODUCT ADMINISTERED (Vaccine administered after more than 1 temperature excursion) in a 29-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 03-Apr-2021 at 3:11 PM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 03-Apr-2021 at 3:11 PM, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Vaccine administered after more than 1 temperature excursion). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccine administered after more than 1 temperature excursion). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccine administered after more than 1 temperature excursion) and POOR QUALITY PRODUCT ADMINISTERED (Vaccine administered after more than 1 temperature excursion) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   The age of patient was provided as 29.98.  Concomitant products were not provided.  On 03-Apr-2021, excursion time was 9 AM, temperature was 34, total doses given for the day was 210, condition of vaccine prior to administration was not frozen, vaccine was moved to fridge on 30-Mar-2021, vial was moved to clinic on 03-Apr-2021. 20 vials were sent to clinic. Vaccine BUD date was 29-Apr-2021.  On 03-Apr-2021, vials were stored in cooler 1, at following time and temperature respectively, 8 AM: 38, 9 AM: 34, 10 AM: 38, 11 AM: 42, 12 PM: 41, 1PM: 41, 2 PM: 41, 3 PM: 40, 4 PM: 40 and 5 PM: 41.  The vials were only punctured right before administration and all doses were drawn from the vial due to high-pace clinic.  Temperature recordings were taken using a traceable temperature monitor at every hour.  After administration, the vial was returned to the freezer/refrigerator, or maintained at room temperature.  It was reported that the patient was administered with vaccine that experienced more than 1 temperature excursion during 33 weeks in 2021. The HCP explained that each time a vial was put into a cooler, there was a period of 1 hour or 1 and half hour approximately, when the temperature data logger registered 34 or 35 degree F.  Treatment medications were not reported.   This case was linked to MOD-2022-566976 (Patient Link).
Received flu shot and Hep A.  3 minutes later standing at check out counter, fell backwards onto floor.  Hit back of head on ground.  Some twitching for 5 secs.  Regained consciousness.  Took water.  Sat up after 5 minutes walked out after 15 mins.
Pt noticed hives from top of left shoulder down to top of hand just red dots all over / no fever no SOB.
This case was reported by a healthcare professional via a sales representative and described the occurrence of not responding to therapy in a female subject of unspecified age who was vaccinated with ENGERIX B (GlaxoSmithKline). Concurrent medical conditions included renal failure. In 2008 the subject received 1st dose, 2nd and 3rd dose of ENGERIX B (unknown) on unspecified dates, and experienced not responding to therapy. Relevant test results included anti-HBs antibody. The reporter stated that the subject had received three doses of ENGERIX B between 04 April 2008 and 19 November 2008. Titers were obtained at an unknown time and were negative for anti-HBs antibodies. Recently, titers were obtained again and anti-HBs were still negative. Follow up information was received on 20 October 2009 from the reporting health care provider. The subject (60-69 years of age) received the ENGERIX B 20mcg/ml, intramuscularly) on 04 April 2008, 03 June 2008, and 18 November 2008. Titers were ordered by another office and resulted in "unmounted" antibodies and requested that the subject was contacted and administered a second series of HEPATITIS B.
chills; arm swollen; feverish; arm got red; This case was reported by a consumer via interactive digital media and described the occurrence of chills in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   Previously administered products included Shingles vaccine (received 1st dose on an unknown date and was fine).   In December 2021, the patient received the 2nd dose of Shingles vaccine. In December 2021, less than 2 weeks after receiving Shingles vaccine, the patient experienced chills, swelling arm, fever and erythema of extremities. On an unknown date, the outcome of the chills, swelling arm, fever and erythema of extremities were recovered/resolved.   It was unknown if the reporter considered the chills, swelling arm, fever and erythema of extremities to be related to Shingles vaccine.  Additional details were provided as follows: The patient self-reported this case. The age at vaccination was not reported. The reporter stated that he/she was fine with his/her first shingles dose but he/she got the second one 9 days before the day of reporting and had a terrible reaction, chills for 3 days, arm got red and swollen and feverish, took a week to calm down. The follow-up would not be possible as no contact details were available.
Left arm swollen, red and hot to touch. Complained of itching at site and hard to lift arm. Went to MD today - given antibiotic, Zyrtec and Benadryl.
intermittent shortness of breath occurring a few hours after vaccination, followed by the onset of an area of swelling above left collarbone (appears consistent with left supraclavicular lymphadenopathy/Virchow Node), left neck pain, onset of rash on bilateral cheeks, temporary left deltoid soreness. Patient has taken OTC advil and symptoms are improving, but lymphadenopathy and rash have not yet fully resolved.
rash & fever day p/vax w/onset of rhinorrhea; scarlet tubination on exam;
MMR and Var given at 5 months of age; immunization card listed DOB as 2-7-2008  when correct date was 2-7-2009
The day I received the first dose 10/13/21 I developed a rash/raised skin on my upper right thigh which is still present on 10/20/21. The following days i developed chest tightness and a dry cough intermittently. On 10/18/21 i felt pain under my right eyelid which worsened at night into a visible puffing and swelling under my right eye. By 10/20/21 this area worsened and is extremely swollen/puffy causing problems with vision. Going to see Dr. at 14:00 hrs. on 10/20/21.
Information has been received from a pharmacist referring to a patient of unknown age and gender. The patient's medical history and concurrent condition were not reported. On 26-MAY-2015 the patient was vaccinated with a dose of improperly stored ZOSTAVAX, (0.65 ml/once), subcutaneously. No adverse effect was reported. Additional information has been requested.
Patient vomited and described being dizzy, weak and shaky at 2:34pm. BP 98/63 at 2:38pm. BP 102/67 at 2:44pm. EMSA arrived at 2:47 and cleared patient to leave.
12hrs p/vax pt devel fever to touch;early AM the day of vax pt devel urticarial, gen eruption & documented fever of 101.2R;
Member has reported was hospitalized on DEC2020, due to flu shot reaction. States got flu shot & had a bad reaction. Event Resolved, but date of resolution not specified. Date of event not specified.
5 minutes after administration, patient became short of breath, had audible stridor and was grabbing at neck. Patient was given IM epinephrine, IV normal saline, IV SOLU-MEDROL, IV BENADRYL, IV famotidine, and albuterol via nebulizer. O2 2L also applied to patient.
Received first dose on 1/4/21 and second dose on 1/25/21.  4/28/21 reported having leg pain and was seen by primary care where it was determined he had a blood clot and was placed on blood thinners.
20 days later developed a splotchy rash consistent with measles rash, no fevers or other symptoms
This spontaneous case was reported by a consumer and describes the occurrence of HEADACHE (real bad headache) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced HEADACHE (real bad headache). At the time of the report, HEADACHE (real bad headache) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       NO Concomitant medication was reported No treatment medication was reported